Drug reference
Ethinylestradiol; Norelgestromin
Progestogen · Contraception
Also known as ORTHO EVRA, Ethinylestradiol, Norelgestromin, Evra
ProgestogenContraception
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Combination oral contraceptives prevent ovulation by suppressing LH and FSH levels, leading to an absence of a mid-cycle LH surge and diminished endogenous steroid levels. The combination of estrogen and progestin synergistically decreases plasma gonadotropin levels and suppresses ovulation more consistently than either component alone.
Indications
ContraceptionContraception in women who are likely to comply poorly with combined oral contraceptives (restricted use)
Dosing
- Adult
- Apply one patch weekly to the buttock, abdomen, upper arm, or torso for 3 consecutive weeks, followed by one patch-free week, completing a 28-day cycle.…
Pharmacokinetics
Duration
Weekly
Bioavailability
Higher estrogen exposure (AUC) than low-dose oral contraceptive pills
Metabolism
Norelgestromin is metabolized to norgestimate
Side effects
Common
Local reactions to the patch (5-15% of users)
Serious
- Venous thromboembolism (potential increased risk due to higher estrogen exposure)
Related guidelines
Other Progestogen drugs
Ask House about Ethinylestradiol; Norelgestromin
Continue into a citation-backed clinical answer with the drug context already attached.